| Chronic Lymphocytic Leukemia
Calquence Tablets vs Rituxan Hycela
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Calquence vs Rituxan Hycela with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRituxan Hycela has a higher rate of injection site reactions vs Calquence based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rituxan Hycela but not Calquence, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Calquence
Rituxan Hycela
At A Glance
Oral
Every 12 hours
BTK inhibitor
SC injection
Every 3-4 weeks
CD20-directed antibody
Indications
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
Dosing
Mantle cell lymphoma 100 mg orally approximately every 12 hours until disease progression or unacceptable toxicity; swallow tablet whole with or without food (monotherapy or in combination with bendamustine and rituximab).
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 100 mg orally approximately every 12 hours until disease progression or unacceptable toxicity (monotherapy, or in combination with obinutuzumab or venetoclax).
Lymphoma, Follicular 1,400 mg/23,400 Units SC; for relapsed/refractory FL, once weekly for 3 or 7 weeks following an initial IV rituximab dose (4 or 8 weeks total); for previously untreated FL, on Day 1 of Cycles 2-8 of chemotherapy every 21 days, then maintenance every 8 weeks for 12 doses; for non-progressing FL after CVP, once weekly for 3 weeks every 6 months to a maximum of 16 doses.
Diffuse Large B-Cell Lymphoma 1,400 mg/23,400 Units SC on Day 1 of Cycles 2-8 of CHOP chemotherapy every 21 days for up to 7 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (up to 6-8 cycles total).
Chronic Lymphocytic Leukemia 1,600 mg/26,800 Units SC on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide every 28 days for 5 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (6 cycles total).
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Upper respiratory tract infection, diarrhea, headache, musculoskeletal pain.
Serious Serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury.
Postmarketing Ventricular arrhythmias, drug induced liver injury.
Most common (>=20%) Infections, neutropenia, nausea, constipation, cough, fatigue (FL); infections, neutropenia, alopecia, nausea, anemia (DLBCL); infections, neutropenia, nausea, thrombocytopenia, pyrexia, vomiting, injection site erythema (CLL).
Serious Mucocutaneous reactions, hepatitis B reactivation, progressive multifocal leukoencephalopathy, hypersensitivity and administration reactions, tumor lysis syndrome, infections, cardiac arrhythmias, renal toxicity, bowel obstruction and perforation.
Postmarketing Prolonged pancytopenia, fatal cardiac failure, uveitis, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease.
Pharmacology
Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK); it and its active metabolite ACP-5862 form a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK enzymatic activity and downstream B-cell proliferation, trafficking, chemotaxis, and adhesion pathways required for B-cell malignancy growth.
Anti-CD20 chimeric murine/human IgG1 monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC); combined with hyaluronidase human, which transiently depolymerizes subcutaneous hyaluronan to enhance rituximab absorption into systemic circulation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Calquence
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Rituxan Hycela
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Calquence
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Rituxan Hycela
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Calquence
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Rituxan Hycela
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Chronic Lymphocytic Leukemia (CLL)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rituxan Hycela.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CalquenceView full Calquence profile
Rituxan HycelaView full Rituxan Hycela profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.